PRINCETON, N.J., Nov. 30 /PRNewswire/ -- Ranbaxy Laboratories Limited (RLL) announced today that the Company is introducing two new anti-HIV products, Virolis-E and Virocomb-E, in India on World AIDS Day, December 1, 2005. Both products contain three Anti-retroviral (ARV) drugs and offer World Health Organization (WHO) recommended first line Highly Active Anti Retroviral Therapy (HAART) in convenient daily use packs.
Commenting on the launch, Dr. Brian Tempest, CEO and Managing Director, RLL said, “We are pleased to introduce Virolis-E and Virocomb-E, two innovative products that aim to make HIV treatment easier to administer and use. Ranbaxy is committed to HIV care and this is yet another step in our endeavor to make high quality, affordable and patient-friendly ARVs available worldwide.”
These Ranbaxy products are designed to improve compliance with HAART, which is presently a challenge faced by both patients and healthcare providers. In most countries outside India, these products will be labeled and sold under the Coviro-E and Avocomb-E brand names respectively.
Virolis-E is a first of its kind product in the world. It is a compliance pack containing two fixed dose combination tablets of Lamivudine 150mg and Stavudine 30/40mg and one tablet of Efavirenz 600mg.
Virocomb-E is also a compliance pack and contains two fixed dose combination tablets of Lamivudine 150mg and Zidovudine 300mg and one tablet of Efavirenz 600mg.
Virolis-E and Virocomb-E are indicated for treatment of HIV-1 infection. These products will make available Efavirenz-based HAART regimens in convenient daily packs in addition to the convenient Nevirapine-based regimens already made available by Ranbaxy.
The products are coded with easy to decipher graphics to indicate the time when drugs need to be consumed. The WHO also encourages such presentation, as they are expected to enhance compliance to anti-HIV therapy.
Ranbaxy’s ARV’s are manufactured at the Company’s state-of-the-art manufacturing facilities that have been inspected and approved by some of the most stringent agencies in the world, including U.S. FDA and WHO. The Contract Research Organizations (CROs) used by Ranbaxy to carry out bio-equivalence studies for its ARV’s are globally reputed and conduct and file their studies routinely with some of the most stringent regulatory authorities around the world.
Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India’s largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.
Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary “platform technologies,” resulting in a number of products under development. The Company is serving its customers in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries.
Ranbaxy Laboratories Limited
CONTACT: Charles M. Caprariello, Vice President, Corporate Communications,of Ranbaxy Inc., +1-609-720-5615; or Edwige Buteau, +1-212-994-7517, orAnuj Baveja, +1-212-994-7552, both of RF Binder Partners Inc., for RanbaxyLaboratories Limited
Web site: http://www.ranbaxy.com/
